Curis, Inc. (NASDAQ:CRIS) Director Marc Rubin bought 25,000 shares of the stock in a transaction that occurred on Thursday, November 16th. The stock was bought at an average price of $0.98 per share, with a total value of $24,500.00. Following the completion of the acquisition, the director now owns 51,596 shares of the company’s stock, valued at approximately $50,564.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Curis, Inc. (NASDAQ:CRIS) traded down $0.05 during trading on Friday, reaching $0.88. 2,084,090 shares of the company were exchanged, compared to its average volume of 677,276. Curis, Inc. has a 52-week low of $0.88 and a 52-week high of $3.53. The company has a quick ratio of 5.15, a current ratio of 5.15 and a debt-to-equity ratio of 1.24.
Curis (NASDAQ:CRIS) last released its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). The company had revenue of $2.44 million during the quarter, compared to analysts’ expectations of $2.19 million. Curis had a negative net margin of 629.29% and a negative return on equity of 250.58%. Curis’s revenue for the quarter was up 38.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.21) earnings per share. research analysts predict that Curis, Inc. will post -0.41 earnings per share for the current year.
Hedge funds have recently made changes to their positions in the business. FNY Partners Fund LP lifted its position in Curis by 350.0% during the third quarter. FNY Partners Fund LP now owns 67,500 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 52,500 shares in the last quarter. Bank of America Corp DE lifted its position in Curis by 58.7% during the first quarter. Bank of America Corp DE now owns 36,348 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 13,448 shares in the last quarter. Prudential Financial Inc. acquired a new position in Curis during the first quarter valued at approximately $105,000. OxFORD Asset Management LLP acquired a new position in Curis during the second quarter valued at approximately $115,000. Finally, Voya Investment Management LLC lifted its position in Curis by 21.8% during the second quarter. Voya Investment Management LLC now owns 68,138 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 12,207 shares in the last quarter. 46.01% of the stock is currently owned by hedge funds and other institutional investors.
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.